Navco Pharmaceuticals Inc.
NAV.V
TSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.82% | -66.62% | |||
| Depreciation & Amortization | -98.04% | 27.50% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.86% | -60.09% | |||
| Operating Income | 14.86% | 60.09% | |||
| Income Before Tax | -395.53% | 55.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -395.53% | 55.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -395.53% | 55.90% | |||
| EBIT | 14.86% | 60.09% | |||
| EBITDA | 6.07% | 65.98% | |||
| EPS Basic | -391.30% | 58.18% | |||
| Normalized Basic EPS | 26.67% | 55.88% | |||
| EPS Diluted | -391.30% | 58.18% | |||
| Normalized Diluted EPS | 26.67% | 55.88% | |||
| Average Basic Shares Outstanding | 3.05% | 3.14% | |||
| Average Diluted Shares Outstanding | 3.05% | 3.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
